RT Journal Article
SR Electronic
T1 An immunologically active, adipose-derived extracellular matrix biomaterial for soft tissue reconstruction: concept to clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.08.20206672
DO 10.1101/2020.10.08.20206672
A1 Amy E. Anderson
A1 Iwen Wu
A1 Alexis J. Parrillo
A1 David R. Maestas, Jr.
A1 Ian Graham
A1 Ada J. Tam
A1 Rachael M. Payne
A1 Jeffrey Aston
A1 Carisa M. Cooney
A1 Patrick Byrne
A1 Damon S. Cooney
A1 Jennifer H. Elisseeff
YR 2020
UL http://medrxiv.org/content/early/2020/10/13/2020.10.08.20206672.abstract
AB Soft tissue reconstruction remains an intractable clinical challenge as current surgical options and synthetic implants may produce inadequate outcomes. Soft tissue deficits may be surgically reconstructed using autologous adipose tissue, but these procedures can lead to donor site morbidity, require multiple trips to the operating room, and have highly variable outcomes. To address the clinical need for soft tissue reconstruction, we developed an “off-the-shelf” adipose matrix from allograft human adipose tissue (acellular adipose tissue, AAT). We applied physical and chemical processing methods to remove lipids and create an injectable matrix that mimicked the properties of fat grafting materials. Biological activity was assessed using cell migration and stem cell adipogenesis assays. Characterization of the regenerative immunology properties in a murine muscle injury model revealed allograft and xenograft AAT induced pro-regenerative CD4+ T cells and macrophages with xenograft AAT attracting additional eosinophils secreting interleukin 4 (Il4). In immunocompromised mice, AAT injections retained similar tissue volumes as human fat grafts but did not have the cysts and calcifications that formed in the human fat graft implants. Combination of AAT with human adipose-derived stem cells (ASCs) resulted in lower implant volumes. However, tissue remodeling and new adipose development increased significantly with the addition of cells. Larger injected volumes of porcine-derived AAT demonstrated biocompatibility and greater volume retention when applied allogeneicly in Yorkshire cross pigs. Under a biologic IND application, AAT was implanted in healthy volunteers in abdominal tissue that was later removed (panniculectomy or abdominoplasty). The AAT implants were well tolerated and biocompatible in all eight human subjects. Analysis of implants removed between 1 and 18 weeks demonstrated increasing cellular infiltration and immune populations, suggesting continued tissue remodeling and the potential for long term tissue replacement.SUMMARY An adipose-derived injectable biomaterial provides volume correction for soft tissue defects while promoting pro-healing immune responses.Competing Interest StatementJ.H.E. holds equity in Aegeria Soft Tissue, a company that has licensed JHU intellectual property for the AAT material used in this study. The conflict is being managed by the Johns Hopkins Office of Policy Coordination. All other authors declare that they have no competing interests.Clinical TrialNCT02817984Funding StatementThis work was supported by the Arms Forces Institute for Regenerative Medicine (AFIRM II).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted with approval from the Johns Hopkins Institutional Review Board (IRB00027657).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data associated with this study are present in the paper or the Supplementary Materials. All primary data and analyses related to this manuscript are available upon request.